Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility
share
Excerpt
Fujifilm’s fifth media manufacturing site to be operated by FUJIFILM Irvine Scientific. It triples the company’s current capacity for liquid cell culture media production and creates over 100 new positions, including bioprocessing engineers, manufacturing, production, and logistics roles.
Article Summary
FUJIFILM Corporation announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will be operated by FUJIFILM Irvine Scientific, Inc., a subsidiary of FUJIFILM Corporation, and a world leader in the development and manufacture of advanced cell culture solutions for life science research, bioproduction, cell therapy manufacturing, and medical applications.
The new facility is planned to ensure that FUJIFILM Irvine Scientific can meet increasing market demands for high quality cell culture media solutions.
With over 250,000 sq. feet and located across 64 acres in RTP, the site will support cGMP manufacturing of animal component-free, dry powder, and liquid media, adding additional production capacity for FUJIFILM Irvine Scientific of 800,000 Kg/year for dry powder, 3,300,000 L/year for liquid, and 40,000 L/day of Water for Injection (WFI).
FUJIFILM Irvine Scientific has experienced rapid growth over the past decade and the forecasted demand for cell culture media to support bioproduction and advanced therapies is projected to grow at a CAGR of 10-12% through 2031. The company made the strategic decision to expand its capacity by constructing manufacturing facilities in biotech centers around the world, To meet the requirements of its customers. This strategy ensures a secure supply chain, and rapid, reliable delivery of products through the development of extensive regional supply networks, critical to supporting cell and gene therapies.
“Fujifilm’s intensive investment in the life sciences field represents our commitment to be the dedicated partner for customers in the biopharmaceutical industry,” said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. “With the enhanced capabilities of our global manufacturing sites for cell culture media, we will continuously contribute to customers’ robust manufacturing process and creation of innovative therapies to make the world a healthier place.”
“Our customers require rapid, reliable delivery of cell culture media to support their commercial production,” said Yutaka Yamaguchi, chairman, and chief executive officer, FUJIFILM Irvine Scientific. “The cell culture media that will be manufactured at this new site in North Carolina will help ensure a steady supply of raw materials for biologics, cell and gene therapies, and other key medicines that are essential to human health. The additional production capacity will ensure we meet the projected demand for cell culture media from our customers worldwide.”
“We’re proud that FUJIFILM Irvine Scientific is the latest company to call the Research Triangle Park home, bringing with it many new job opportunities,” said Wake County Board of Commissioners Chair Sig Hutchinson. “Like many other global businesses, Fujifilm recognizes the value our region offers life sciences companies by providing top talent, easy access to transportation, and a quality of life that is second to none.”
About FUJIFILM Irvine Scientific
FUJIFILM Irvine Scientific, Inc. is a global leader in the innovation and manufacture of cell culture solutions for Life Science and Medical markets, providing products and services that assist our customers in advancing healthcare initiatives. Working across discovery research, cell and gene therapy, reproductive medicine and cytogenetics, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers, manufacturers, and clinicians. For over 50 years, our Mission has been to set the standard for excellence in our products and custom solutions to enable our customers to advance healthcare. Our facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth. FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.
(Source: FUJIFILM, 22th Nov 2022)
Comments
Leave A Comment
Leave a Reply
